Sandy Spring Bank decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,620 shares of the biopharmaceutical company’s stock after selling 2,614 shares during the quarter. Sandy Spring Bank’s holdings in Gilead Sciences were worth $2,910,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also modified their holdings of GILD. Capital International Investors grew its holdings in shares of Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock valued at $908,803,000 after buying an additional 5,205,983 shares in the last quarter. Sanders Capital LLC grew its holdings in shares of Gilead Sciences by 102.9% during the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock valued at $757,119,000 after buying an additional 5,026,015 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of Gilead Sciences by 230.0% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after buying an additional 3,434,450 shares in the last quarter. CI Global Investments Inc. grew its holdings in shares of Gilead Sciences by 5,461.1% during the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock valued at $237,675,000 after buying an additional 3,257,969 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Gilead Sciences by 35.0% during the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after buying an additional 2,700,600 shares in the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.
In related news, Director Gayle E. Wilson sold 60,000 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $77.92, for a total transaction of $4,675,200.00. Following the completion of the transaction, the director now owns 182,258 shares of the company’s stock, valued at approximately $14,201,543.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP James R. Meyers sold 100,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total value of $8,024,000.00. Following the transaction, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. Insiders sold 430,268 shares of company stock valued at $34,074,395 in the last ninety days. Insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) opened at $79.51 on Friday. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $89.54. The firm has a market capitalization of $106,238.41, a PE ratio of 22.85, a price-to-earnings-growth ratio of -1.86 and a beta of 1.24. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the previous year, the firm earned $2.70 earnings per share. The business’s quarterly revenue was down 18.7% compared to the same quarter last year. sell-side analysts expect that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a $0.57 dividend. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.87%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 59.77%.
A number of brokerages have recently weighed in on GILD. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Credit Suisse Group set a $80.00 price target on Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, January 3rd. Leerink Swann lowered their price target on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a report on Wednesday, February 7th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price on the stock in a research note on Monday, February 19th. Finally, Barclays restated an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $88.61.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.